114th Congress (Current)
The MDA Advocacy department continues to strive to be an effective voice for the hundreds of thousands of Americans whom we serve. As legislation relevant to our neuromuscular community is introduced throughout the 114th Congress, we will provide detailed overviews of the issues, as well as helpful tools to take action.
21st Century Cures
This is an initiative in the U.S. House of Representatives to advance medical research and accelerate the discovery, development and delivery of treatments and cures, especially for those with unmet medical needs. The initiative was introduced in 2014 by Rep. Fred Upton (R-MI) and Rep. Diana DeGette (D-CO) and has evolved into draft legislative language that addresses issues including incorporating patient perspectives into the regulatory review process, modernizing clinical trials, and streamlining regulatory processes. MDA has been, and will continue to be, engaged in this initiative.
Ensuring Access to Clinical Trials Act of 2015 (“EACT”) (S.139/H.R.209)
New Legislation Would Ensure Access to Clinical Trials for People with Neuromuscular Diseases
The Muscular Dystrophy Association has partnered with more than 75 organizations—who together represent millions of individuals—in support of the Ensuring Access to Clinical Trials Act of 2015 (“EACT”).
Increase Funding for the National Institutes of Health (NIH)
Increased funding for the National Institutes of Health (NIH) is critical to finding treatments and cures for the neuromuscular diseases that affect the MDA community. MDA works hard every day to raise money from generous supporters to fund groundbreaking research and bring critical support to families, but collaboration—including leveraging federal funding—is what will help speed urgently needed treatments to families.
Ensuring Access to Quality Complex Rehabilitative Technology Act of 2015 (“CRT”) (H.R.1516)
Introduced in the House of Representatives on March 19, 2015, by Rep. James Sensenbrenner (R-WI-05) and with bi-partisan support, the Ensuring Access to Quality Complex Rehabilitation Technology Act would create a separate benefit category under Medicare for complex rehabilitation technology (CRT), which includes products such as complex rehabilitation power wheelchairs, highly configurable manual wheelchairs, adaptive seating and positioning systems, and other specialized equipment, such as standing frames and gait trainers.
Muscular Dystrophy Association — USA
222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2015, Muscular Dystrophy Association Inc. All rights reserved.